QingSong Health Corporation (HKEX: 02661) has repurchased 1.34 million ordinary shares on 30 June 2026, classifying them as treasury shares. The on-market transactions were executed within a price band of HK$12.10 to HK$13.48 per share, translating into a volume-weighted average cost of HK$12.3142 and an aggregate consideration of approximately HK$16.50 million.

Following the buyback, the company’s outstanding share count (excluding treasury shares) fell from 205.67 million to 204.33 million, a reduction of 1.34 million shares, or 0.65%. Concurrently, the treasury-share balance rose to 2.04 million shares, while the total number of issued shares remained unchanged at 206.37 million.

The transaction forms part of QingSong Health’s share repurchase mandate approved on 22 May 2026, which authorises the company to buy back up to 20.64 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, equivalent to 0.99% of the company’s issued share capital as of the mandate date.

In accordance with Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 30 July 2026. QingSong Health’s board confirmed that the repurchase complied with all applicable laws, listing rules and internal authorisations.